logo
Grammarly secures $1 billion from General Catalyst to build AI productivity platform

Grammarly secures $1 billion from General Catalyst to build AI productivity platform

Time of India30-05-2025
Grammarly
has raised $1 billion in non-dilutive financing from General Catalyst to expand its artificial intelligence (AI) offerings, aiming to grow into a comprehensive productivity platform, the companies said on Thursday.
Grammarly, known for its popular writing assistant tool, plans to use the capital to fund sales and marketing costs and strategic acquisitions. It looks to use AI to build more communication-based productivity tools and even hosts third-party tools on its platform by leveraging access to its 40 million daily users.
The investment, one of the biggest out of General Catalyst's Customer Value Fund (CVF), could help late-stage tech companies like Grammarly accelerate growth by using dedicated capital to acquire new customers. By reallocating funds typically tied up in sales and marketing, Grammarly can invest more in product development.
In return, General Catalyst doesn't receive an equity stake in Grammarly, but will get a capped return linked to revenue generated through using this capital. This is structured as a percentage of the revenue generated from the fund being used in customer acquisition.
Founded in 2009, Grammarly has an annual revenue exceeding $700 million and is profitable. In December, Grammarly appointed Shishir Mehrotra, previously CEO of the acquired productivity platform Coda, as its new leader, signaling a push into broader AI-powered workplace tools.
Live Events
"As Grammarly is going through a huge transformation of going from being a what is mostly known as a single-purpose agent to being an agent platform, it just felt very important for us to be able to bet big in our product development and in M&A as well as in our growth strategies," Mehrotra said in an interview.
Discover the stories of your interest
Blockchain
5 Stories
Cyber-safety
7 Stories
Fintech
9 Stories
E-comm
9 Stories
ML
8 Stories
Edtech
6 Stories
He added said the company has an eventual goal to go public, although no imminent plans.
"I'm right now just focused on making sure we're innovating with new products, growing as fast as we can. But when we feel ready, we'll go public," Mehrotra added.
The dedicated growth investment, if it pays off, could also benefit the valuation of Grammarly and General Catalyst's stake in the company, as it has also been an equity investor in Grammarly's series B funding in 2017.
San Francisco-based Grammarly has raised over $550 million in venture capital, according to PitchBook. It was last valued at $13 billion in 2021.
General Catalyst's Customer Value Fund operates apart from the firm's main venture funds with separate limited partners, and is not included in the newly raised $8 billion fundraising the firm announced.
This approach is part of a strategic evolution for the tech investor, led by CEO Hemant Taneja, as it seeks to grow beyond the traditional venture capital model, including creating innovative funding mechanisms.
Its customer acquisition fund has invested in nearly 50 companies, including Lemonade and Fivetran, as it leads on growth metrics to a more predictable path to returns.
"Companies like Grammarly basically have a machine where they can invest dollars in sales and marketing and generate a very consistent return," said Pranav Singhvi, Managing Director at General Catalyst, "With this wave of AI, giving Grammarly the firepower to actually go and invest could land those customers beyond the 40 million."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Chennai Metrowater pilots robotic cleaning in sewage pumping stations to boost efficiency and workers' safety
Chennai Metrowater pilots robotic cleaning in sewage pumping stations to boost efficiency and workers' safety

The Hindu

time2 hours ago

  • The Hindu

Chennai Metrowater pilots robotic cleaning in sewage pumping stations to boost efficiency and workers' safety

After deploying robots to clean sewer lines in some city zones, Chennai Metrowater is now piloting the use of robotic technology in sewage pumping stations in Thiruvanmiyur. The initiative aims to enhance operational safety and efficiency by minimising manual intervention. The water agency has already added Bandicoot Mobility, a robot that cleans maintenance holes of the sewer network, to remove clogged waste in sewer lines in zone 6 ( 9 (Teynampet) and 13 (Adyar). With robotic devices, which were developed by Genrobotics, a Kerala-based startup, helping to reduce clogging of lines for a year now, the water agency is exploring other innovative technologies to improve maintenance of sewer infrastructure. Officials of the Metrowater said an advanced robot with remote control unit and cameras, Wilboar, is being used to clean the sewage wells in Thiruvanmiyur sewage pumping station on a pilot basis. The robotic unit developed by Genrobotics is lowered into the wells that have a depth of up to 10 metre to remove the silt. With high-pressure water jets and grinders, the device grinds accumulated sludge into finer particles and clears them. This would eliminate the challenges in the use of conventional processes, improve efficiency of cleaning sewer wells and reduce complaints of sewage overflow in the pipelines. The Thiruvanmiyur sewage pumping station has a capacity to handle 15 million litres of sewage a day. Such robotic devices are already in use at Nellore, Andhra Pradesh and Thiruvananthapuram, Kerala, said officials. There are 375 sewage pumping stations in the city. Such robotic devices would be deployed in sewer well cleaning operations in other pumping stations following the success of the trial implementation. Rao, president, Chennai Metropolitan Water Supply and Sewerage Board Labourers Union, said it was a welcome initiative to ensure workers' safety and reduce manual intervention. Such efforts must be expanded to densely populated urban spaces and monitored for regular maintenance. Workers hired for sewer network maintenance should be redeployed to other roles. Nearly 2,850 labourers have been hired for sewer and water network maintenance in Chennai.

Logistics played key role in Operation Sindoor success, says Rajnath Singh
Logistics played key role in Operation Sindoor success, says Rajnath Singh

Economic Times

time2 hours ago

  • Economic Times

Logistics played key role in Operation Sindoor success, says Rajnath Singh

Synopsis Defence Minister Rajnath Singh lauded Indian agencies for their seamless logistics management during Operation Sindoor, emphasizing its crucial role in the operation's success. He highlighted that modern warfare relies not only on weaponry but also on the timely delivery of resources. Seamless logistics management by Indian agencies-from mobilisation of the armed forces to delivering equipment at the right time and place-was a deciding factor in the success of Operation Sindoor, defence minister Rajnath Singh said on Sunday. ADVERTISEMENT In a virtual address at the convocation ceremony of Vadodara-based Gati Shakti Vishwavidyalaya (GSV), the minister said in the current era, wars are not just won by guns and bullets but by time-bound delivery of material, highlighting Op Sindoor as an example of excellent logistics management. "Whether it's soldiers fighting on the border or personnel engaged in disaster management, without coordination or proper management of resources, even the strongest of intentions weaken. Logistics is the power that transforms chaos into control. Power is measured not only by weapons, but also by timely resource management. Be it war, disaster or global pandemic, the nation which keeps its logistics chain strong is the most stable, secure and capable," he said. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online. NEXT STORY

Cheaper cancer care therapy earns big bucks for pharma company
Cheaper cancer care therapy earns big bucks for pharma company

Economic Times

time2 hours ago

  • Economic Times

Cheaper cancer care therapy earns big bucks for pharma company

India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store